---
title: "Arrowhead Pharmaceuticals soars 20% as plozasiran hits Phase 3 endpoints"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293482101.md"
description: "Arrowhead (ARWR) jumps 20% after plozasiran meets primary endpoints in Phase 3 trials, cutting triglycerides by up to 81%."
datetime: "2026-07-22T13:40:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293482101.md)
  - [en](https://longbridge.com/en/news/293482101.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293482101.md)
---

# Arrowhead Pharmaceuticals soars 20% as plozasiran hits Phase 3 endpoints

箭头制药 (ARWR.US) 盘中涨近 20%，现报 89.33 美元。

公司旗下药物 plozasiran 在严重高甘油三酯血症的Ⅲ期 SHASTA-3 和 SHASTA-4 试验中达到主要终点，甘油三酯中位数降幅分别达**79%**和**81%**，显著优于安慰剂组的**27%**。汇总数据显示急性胰腺炎事件显著减少，高危亚组降幅达**100%**。公司计划于 2026 年底向美国 FDA 提交补充新药申请，完整数据将于 8 月 30 日在欧洲心脏病学大会公布。

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone](https://longbridge.com/en/news/294635779.md)
- [Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat](https://longbridge.com/en/news/293509194.md)
- [Tarsus Pharmaceuticals (TARS) Could Be 38% Undervalued Following Cautious Earnings Expectations](https://longbridge.com/en/news/294318126.md)
- [Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/294039544.md)
- [GH Research (GHRS) to Announce Earnings on Thursday](https://longbridge.com/en/news/294319262.md)